Skip to main content

Table 4 Exploratory analysis of relationships between overall activity impairment outcomes and type of drug received

From: Effect of subcutaneous tocilizumab treatment on work/housework status in biologic-naïve rheumatoid arthritis patients using inverse probability of treatment weighting: FIRST ACT-SC study

Activity impairment measures TCZ-SC group csDMARDs-alone group
n Standardized regression coefficient 95% CI P value n Standardized regression coefficient 95% CI P value
Presenteeism (%) 143 −0.4861 −0.6470, −0.3252 < 0.0001 148 −0.4328 −0.5887, −0.2769 < 0.0001
Overall work impairment (%) 143 −0.4819 −0.6437, −0.3202 < 0.0001 148 −0.3913 −0.5491, −0.2336 < 0.0001
Activity impairment (%) 143 −0.6345 −0.7747, −0.4943 < 0.0001 148 −0.6486 −0.7876, −0.5096 < 0.0001
HAQ-DI 143 −0.4828 −0.6415, −0.3241 < 0.0001 148 −0.1584 −0.3360, 0.0201 0.0815
EQ-5D 143 0.3635 0.1960, 0.5311 < 0.0001 148 0.3181 0.1446, 0.4916 0.0004
DAS28-ESR 143 −0.3305 −0.4950, −0.1661 0.0001 148 −0.1802 −0.3533, −0.0072 0.0414
CDAI 143 −0.1950 −0.3674, −0.0226 0.0270 148 −0.1127 −0.2819, 0.0564 0.1897
SDAI 143 −0.2289 −0.4003, −0.0576 0.0092 148 −0.1113 −0.2810, 0.0585 0.1971
WFun 143 −0.3549 −0.5266, −0.1832 < 0.0001 148 −0.1680 −0.3353, −0.0007 0.0491
K6 143 −0.1895 −0.3661, −0.0130 0.0355 148 −0.1497 −0.3216, 0.0222 0.0873
  1. CDAI clinical disease activity index, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-ESR disease activity score in 28 joints using the erythrocyte sedimentation rate, EQ-5D EuroQol 5 dimension, HAQ-DI health assessment questionnaire disability index, K6 6-item Kessler psychological distress scale, SDAI simplified disease activity index, TCZ-SC tocilizumab by subcutaneous injection, WFun work functioning impairment scale